18 Mar 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
11 Mar 2026 by admin in UncategorizedComments Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
23 Feb 2026 by admin in UncategorizedComments Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
11 Feb 2026 by admin in UncategorizedComments Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
09 Feb 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
12 Jan 2026 by admin in UncategorizedComments Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
05 Jan 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
21 Dec 2025 by admin in UncategorizedComments Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
15 Dec 2025 by admin in UncategorizedComments Zenas BioPharma’s Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
26 Nov 2025 by admin in UncategorizedComments Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
24 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
19 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
17 Nov 2025 by admin in UncategorizedComments NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
23 Oct 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors
16 Oct 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16 Oct 2025 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA)
08 Oct 2025 by admin in UncategorizedComments Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
07 Oct 2025 by admin in UncategorizedComments Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
22 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces $60 Million Series B Financing
10 Sep 2025 by admin in UncategorizedComments Design Therapeutics Appoints Justin Gover to Board of Directors
02 Sep 2025 by admin in UncategorizedComments Zenas BioPharmand Royalty Pharma Enter into Obexelimab Funding Agrement for up to $30 Milion $300 Million
02 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
21 Aug 2025 by admin in UncategorizedComments Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
08 Jul 2025 by admin in UncategorizedComments U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer
08 Jul 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
30 Jun 2025 by admin in UncategorizedComments Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
26 Jun 2025 by admin in UncategorizedComments Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
16 Jun 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
11 Jun 2025 by admin in UncategorizedComments Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
21 Apr 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
17 Apr 2025 by admin in UncategorizedComments Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
17 Apr 2025 by admin in UncategorizedComments Adicet Bio Appoints Michael Grissinger to the Board of Directors
07 Apr 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Haley Laken, Ph.D., as Chief Scientific Oficer April 7, 2025
07 Apr 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Laura Sepp-Lorenzino, Ph.D., to Its Board of Directors
20 Mar 2025 by admin in UncategorizedComments Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
17 Mar 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Oficer and Chief Medical Officer
10 Jan 2025 by admin in UncategorizedComments Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
